Published in BMJ on August 15, 1998
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis (2011) 3.13
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health (2001) 2.02
Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J (2006) 1.97
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health (2000) 1.78
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Updating the infection risk reduction hierarchy: preventing transition into injection. J Urban Health (2004) 1.49
HIV and hepatitis C among injecting drug users. BMJ (1998) 1.41
Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health (2001) 1.39
Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction (2012) 1.38
The HCV Synthesis Project: scope, methodology, and preliminary results. BMC Med Res Methodol (2008) 1.34
Positive deviance control-case life history: a method to develop grounded hypotheses about successful long-term avoidance of infection. BMC Public Health (2008) 1.33
Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City. J Urban Health (2004) 1.20
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Minimising harm from hepatitis C virus needs better strategies. BMJ (2000) 1.14
Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep (2010) 1.02
Syringe availability as HIV prevention: a review of modalities. J Urban Health (2000) 1.02
A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J (2006) 1.01
Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. J Urban Health (2005) 1.01
The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduct J (2008) 0.99
Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling. Sex Transm Infect (2005) 0.98
Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. J Urban Health (2008) 0.97
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat (2007) 0.94
Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003. Am J Public Health (2006) 0.94
Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol (2004) 0.92
Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology (2014) 0.91
Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon (2013) 0.91
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. BMC Pregnancy Childbirth (2015) 0.88
Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduct J (2005) 0.88
Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infect Dis (2014) 0.86
Correlates and contexts of US injection drug initiation among undocumented Mexican migrant men who were deported from the United States. AIDS Behav (2012) 0.85
Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis (2014) 0.81
Prescription opioid misuse and its relation to injection drug use and hepatitis C virus infection: protocol for a systematic review and meta-analysis. Syst Rev (2014) 0.80
The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduct J (2008) 0.80
What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. Int J Equity Health (2005) 0.79
Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine (2014) 0.78
The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health (2005) 0.77
Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infect Dis (2010) 0.77
A Mismatch between High-Risk Behaviors and Screening of Infectious Diseases among People Who Inject Drugs in Dar es Salaam, Tanzania. PLoS One (2016) 0.75
Health effects of prisons. Many injectors stop injecting while imprisoned. BMJ (2000) 0.75
Following Up Crack Users after Hospital Discharge Using Record Linkage Methodology: An Alternative to Find Hidden Populations. Biomed Res Int (2015) 0.75
Outlier populations: individual and social network correlates of solvent-using injection drug users. PLoS One (2014) 0.75
Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat (2016) 0.75
Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav (2016) 0.75
Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. Addiction (2017) 0.75
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust (1993) 3.28
A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol (1993) 2.61
Hepatitis C virus in intravenous drug users. Med J Aust (1990) 2.33
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06
Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust (1997) 2.03
Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med (1992) 2.01
Spread of bloodborne viruses among Australian prison entrants. BMJ (1995) 1.80
Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1991) 1.76
Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol (1993) 1.73
Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS (1992) 1.55
Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J Med Virol (1995) 1.41
HIV prevalence among IDUs in Australia: a methodological review. Drug Alcohol Rev (1993) 1.36
Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV. Eur J Epidemiol (1994) 1.24
Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med (1994) 1.13
Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. J Gastroenterol Hepatol (1994) 1.11
Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver (1995) 1.07
Hepatitis C virus infection in intravenous drug users: prevalence and risk factors. Scand J Infect Dis (1990) 1.02
Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol (1994) 0.96
Viral hepatitis and drugs: a continuing problem. Int J Epidemiol (1993) 0.93
Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol (1995) 0.91
Hepatitis C and the history of injecting drug use in South Australia. Med J Aust (1994) 0.90
Hepatitis C and the history of injecting drug use in South Australia. Med J Aust (1994) 0.89
[Hepatitis A, B and C as desmoteric infections]. Gesundheitswesen (1993) 0.86
Transmission of hepatitis C virus but not human immunodeficiency virus type 1 following sharing of cleaned injecting equipment. Genitourin Med (1994) 0.85
[Prevalence of antibody to hepatitis C virus in 177 drug addicts]. Zhonghua Liu Xing Bing Xue Za Zhi (1993) 0.84
Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. N Z Med J (1995) 0.83
Hepatitis C virus infection in Iceland: a recently introduced blood-borne disease. Epidemiol Infect (1994) 0.83
SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast. Genes Dev (1997) 7.81
Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science (1999) 7.51
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (2001) 5.14
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28
Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet (1997) 2.97
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
Reversal of resistance to Bacillus thuringiensis in Plutella xylostella. Proc Natl Acad Sci U S A (1994) 2.68
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68
For love or money? An exploratory study of why injecting drug users participate in research. Addiction (2001) 2.50
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
Development of Bacillus thuringiensis CryIC Resistance by Spodoptera exigua (Hubner) (Lepidoptera: Noctuidae). Appl Environ Microbiol (1995) 2.36
TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol (2001) 2.28
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Clinical spectrum of HIV/AIDS in the Asia-Pacific region. AIDS (1998) 2.19
Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat (2009) 2.18
HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16
Trends in infectious disease mortality in Australia, 1979-1994. Med J Aust (1998) 2.02
Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ (1997) 1.92
Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust (2000) 1.92
Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev (2001) 1.91
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82
Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat (2005) 1.74
Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer (1988) 1.74
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect (2006) 1.59
Perinatal exposure to HIV in Australia, 1982-1994. Med J Aust (1997) 1.54
Survival analyses of randomized clinical trials adjusted for patients who switch treatments. Stat Med (1996) 1.54
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52
Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol (1997) 1.52
Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust (2000) 1.50
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation. J Biol Chem (1999) 1.47
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46
Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology (2008) 1.44
Oral contraceptives and breast cancer: a national study. Br Med J (Clin Res Ed) (1986) 1.44
Detection of HCV RNA in semen. Lancet (2000) 1.41
Use of interventions for reducing mother-to-child transmission of HIV in Australia. Med J Aust (2001) 1.40
Sexually transmissible diseases surveillance in Australia: towards a coordinated national system. Commun Dis Intell (1998) 1.40
Premature mortality in Australia 1983-1992, the first decade of the AIDS epidemic. Med J Aust (1995) 1.40
Potential organ donor audit in Ireland. Ir Med J (2011) 1.39
HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39
Reporting of occupational exposures to blood-borne pathogens in Australian teaching hospitals. Med J Aust (1995) 1.38
Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer (1987) 1.37
Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med (2007) 1.36
Activators of protein kinase C induce dissociation of CD4, but not CD8, from p56lck. Science (1989) 1.34
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee. Am J Public Health (1994) 1.32
Circumcision and male-to-male sexual transmission of HIV. AIDS (2001) 1.30
Kaposi's sarcoma and protection from AIDS dementia complex. AIDS (1998) 1.30
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis (2000) 1.29
HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. Med J Aust (1997) 1.26
HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS (1998) 1.24
Predictors of recent HIV testing in homosexual men in Australia. HIV Med (2002) 1.23
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat (2007) 1.23
Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat (2010) 1.23
The benefits and risks of mammographic screening for breast cancer. Epidemiol Rev (1992) 1.23
The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend (2005) 1.23
HIV surveillance in hard-to-reach populations. AIDS (2001) 1.22
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
Self-report is a valid measure of circumcision status in homosexual men. Sex Transm Infect (2008) 1.18
Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer (1987) 1.15
A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology (1995) 1.14
HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans R Soc Trop Med Hyg (1999) 1.09
Binding of Bacillus thuringiensis Cry1Ac Toxin to Aminopeptidase in Susceptible and Resistant Diamondback Moths (Plutella xylostella). Appl Environ Microbiol (1997) 1.09
Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.08
Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. HIV Med (2009) 1.08
Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat (2015) 1.05
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect (2006) 1.04
T1762/A1764 variants of the basal core promoter of hepatitis B virus; serological and clinical correlations in Chinese patients. Liver (1999) 1.04
Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat (2011) 1.02
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab (2000) 1.02
HIV prevalence at reception into Australian prisons, 1991-1997. Med J Aust (1999) 1.01
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01
Secondary malignancies following cancer chemotherapy. Acta Oncol (1994) 0.99
Age-specific HIV incidence among homosexually active men in Australia. Med J Aust (1996) 0.98
A case-control study of diet and breast cancer in Argentina. Int J Cancer (1989) 0.98
Fertility and reproductive choice in women with HIV-1 infection. AIDS (1997) 0.95
Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis (1997) 0.94
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res Hum Retroviruses (1998) 0.94
The usage and costs of health services for HIV infection in Australia. AIDS (1995) 0.94